Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed
Colorectal Neoplasms
About this trial
This is an interventional treatment trial for Colorectal Neoplasms focused on measuring Colorectal, Liver Metastases, Vaccine, Colorectal Liver Metastases
Eligibility Criteria
Inclusion Criteria: Colorectal adenocarcinoma with metastases confined only to the liver, histologically proven and considered suitable for treatment by surgical resection. World Health Organisation (WHO) performance status of 0 or 1 All toxic manifestations of previous treatment must have resolved. Exceptions to this are alopecia or certain Grade 1 toxicities which in the opinion of the Investigator and Cancer Research UK should not exclude the patient. Exclusion Criteria: Radiotherapy, endocrine therapy, immunotherapy, systemic steroids, or chemotherapy during the previous four weeks (six weeks for nitrosoureas and Mitomycin-C) prior to treatment or during the course of the trial. Patients who are high medical risks because of non-malignant systemic disease, including those with active uncontrolled infection. Concurrent serious infections within the 28 days prior to entry to the trial Current malignancies at other sites, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Patients known to be serologically positive for Hepatitis B, C or HIV History of allergy to vaccinations or egg proteins. Inflammatory bowel disease History of autoimmune disease Clinical evidence of cerebral metastases